Filing Flows › Jaguar Health (JAGX) › Q4 2025
Jaguar Health (JAGX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 7, 2026
Jaguar Health (JAGX) reported revenue of $3.2M for the fourth quarter 2025 (Q4 2025), -8% from a year earlier and +5% from the quarter before. Operating margin was -656.6%, net loss $23.2M (716.9% of revenue).
Jaguar Health, Q4 2025: revenue $3.2M (-8% year over year), operating margin -656.6%, net loss $23.2M, operating cash flow −$5.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.2M | +5% | -8% |
| Operating profit | −$21.2M | — | — |
| Net earnings | −$23.2M | — | — |
| Operating cash flow | −$5.5M | — | — |
What changed
Revenue was $3.2M in Q4 2025, down 8% year over year and up 5% from the previous quarter. Product was the largest line at 99% of revenue.
Operating costs exceeded revenue by $21.2M, an operating margin of -656.6%. Total costs grew 110% against a revenue fall of 8%. The fastest-growing cost line was Cost of revenue (+295%). The quarter ended with a net loss of $23.2M, wider than the previous quarter's $9.6M loss.
Operating cash flow was −$5.5M. Non-cash charges added back $477K of depreciation and amortization and $116K of share-based compensation. Working capital and other items added $17.1M.
Questions
What was Jaguar Health's revenue in the fourth quarter 2025?
Jaguar Health (JAGX) reported revenue of $3.2M for the fourth quarter 2025 (Q4 2025), -8% from a year earlier and +5% from the quarter before.
Was Jaguar Health profitable in the fourth quarter 2025?
Operating loss was $21.2M (-656.6% of revenue) and net loss $23.2M.
Source: Jaguar Health 10-K on SEC EDGAR.